Investments in Variable Interest Entities (Details) - USD ($) $ in Millions	9 Months Ended
Sep. 30, 2017	Dec. 31, 2016
Variable Interest Entity [Line Items]
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities	$ 49.7	$ 47.4
Neurimmune
Variable Interest Entity [Line Items]
Research and development cost in support of collaboration agreement	100.00%

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

No definition available.

Name:	us-gaap_VariableInterestEntityLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration